Delusions in Patients with Dementia with Lewy Bodies and the Associated Factors
Table 3
Two models of risk estimates (odds ratios) for core and suggestive features between the delusional and nondelusional patients with DLB.
Features
N (%)
Model 1
Model 2
Delusional
Nondelusional
OR (95% CI)
p
OR (95% CI)
p
N
106
101
Clinical features
Fluctuation
62 (58.5%)
44 (43.6%)
1.83 (1.05–3.17)
0.032
1.52 (0.84–2.73)
NS
Visual hallucinations
65 (61.3%)
35 (34.7%)
2.99 (1.70–5.27)
<0.001
2.26 (1.21–4.21)
0.010
Parkinsonism
96 (90.6%)
87 (86.1%)
1.54 (0.65–3.66)
NS
1.26 (0.49–3.25)
NS
RBD
44 (41.5%)
45 (44.6%)
0.88 (0.51–1.53)
NS
1.18 (0.66–2.12)
NS
Neuroleptic sensitivity
12 (11.3%; 54.5%)
7 (6.9%; 58.3%)
1.71 (0.65–4.55)
NS
1.72 (0.61–4.83)
NS
Vascular risk factors
Hypertension
52 (49.1%)
45 (44.6%)
1.10 (0.63–1.92)
NS
1.17 (0.65–2.09)
NS
Diabetes
21 (19.8%)
40 (39.6%)
0.36 (0.19–0.68)
0.002
0.28 (0.14–0.56)
<0.001
Coronary artery disease
7 (6.6%)
7 (6.9%)
0.93 (0.31–2.81)
NS
0.82 (0.26–2.60)
NS
Hyperlipidemia
4 (3.8%)
5 (5.0%)
0.84 (0.22–3.26)
NS
0.80 (0.20–3.21)
NS
Arrhythmia
9 (8.5%)
13 (12.9%)
0.67 (0.27–1.67)
NS
0.55 (0.21–1.46)
NS
Cerebrovascular disease
16 (15.1%)
19 (18.8%)
0.58 (0.33–1.02)
NS
0.63 (0.29–1.38)
NS
DLB: dementia with Lewy bodies; RBD: REM sleep behavior disorder; NS: not significant. The odds ratio (OR) and 95% confidence interval (CI) were calculated with the nondelusional group as reference. Severe neuroleptic sensitivity (among all patients; among those who had ever used antipsychotics). Model 1 ORs were adjusted for age and gender. Model 2 ORs were adjusted for age, gender, disease severity, antipsychotics, and antiparkinsonian agents.
